These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30701618)

  • 41. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid.
    Esparza I; Kissel T
    Vaccine; 1992; 10(10):714-20. PubMed ID: 1523881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations.
    Pollet J; Versteeg L; Rezende W; Strych U; Gusovsky F; Hotez PJ; Bottazzi ME
    Vaccine; 2017 Mar; 35(10):1410-1416. PubMed ID: 28190745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.
    Little SF; Ivins BE; Webster WM; Norris SL; Andrews GP
    Vaccine; 2007 Apr; 25(15):2771-7. PubMed ID: 17240008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice.
    Zurbriggen R; Glück R
    Vaccine; 1999 Mar; 17(11-12):1301-5. PubMed ID: 10195764
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of an animal model to assess the immunogenicity of single-dose tetanus and diphtheria vaccines based on controlled release from biodegradable polymer microspheres.
    Gupta RK; Griffin P; Rivera R; Siber GR
    Dev Biol Stand; 1998; 92():277-87. PubMed ID: 9554282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved immunogenicity of tetanus toxoid by Brucella abortus S19 LPS adjuvant.
    Mohammadi M; Kianmehr Z; Kaboudanian Ardestani S; Gharegozlou B
    Iran J Immunol; 2014 Sep; 11(3):189-99. PubMed ID: 25266004
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.
    Misiak A; Leuzzi R; Allen AC; Galletti B; Baudner BC; D'Oro U; O'Hagan DT; Pizza M; Seubert A; Mills KHG
    Vaccine; 2017 Sep; 35(39):5256-5263. PubMed ID: 28823618
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of porcine P[6], P[7]-specific △VP8* rotavirus subunit vaccines with a tetanus toxoid universal T cell epitope.
    Wen X; Wei X; Ran X; Ni H; Cao S; Zhang Y
    Vaccine; 2015 Aug; 33(36):4533-9. PubMed ID: 26192360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant.
    Zivkovic I; Petrusic V; Stojanovic M; Inic-Kanada A; Stojicevic I; Dimitrijevic L
    Innate Immun; 2012 Apr; 18(2):333-42. PubMed ID: 21926163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.
    Garçon N; Morel S; Didierlaurent A; Descamps D; Wettendorff M; Van Mechelen M
    BioDrugs; 2011 Aug; 25(4):217-26. PubMed ID: 21815697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The context of tetanus toxoid application influences the outcome of antigen-specific and self-directed humoral immune response.
    Stojanović M; Zivković I; Inić-Kanada A; Petrusić V; Mićić M; Dimitrijević L
    Microbiol Immunol; 2009 Feb; 53(2):89-100. PubMed ID: 19291092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Parallel Effects of Methamphetamine on Anxiety and CCL3 in Humans and a Genetic Mouse Model of High Methamphetamine Intake.
    Huckans M; Wilhelm CJ; Phillips TJ; Huang ET; Hudson R; Loftis JM
    Neuropsychobiology; 2017; 75(4):169-177. PubMed ID: 29402784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association between immunogenicity and adsorption of a recombinant Streptococcus pneumoniae vaccine antigen by an aluminum adjuvant.
    Levesque PM; Foster K; de Alwis U
    Hum Vaccin; 2006; 2(2):74-7. PubMed ID: 17012880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
    Berthold I; Pombo ML; Wagner L; Arciniega JL
    Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Booster vaccination against diphtheria and tetanus in man. Comparison of three different vaccine formulations--III.
    Aggerbeck H; Wantzin J; Heron I
    Vaccine; 1996 Sep; 14(13):1265-72. PubMed ID: 8961516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of nanoparticle adjuvants to potentiate the immune response against diphtheria toxoid.
    Alshanqiti FM; Al-Masaudi SB; Al-Hejin AM; El-Baky NA; Redwan EM
    Hum Antibodies; 2018 Feb; 26(2):75-85. PubMed ID: 29171990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alum adjuvanticity: unraveling a century old mystery.
    De Gregorio E; Tritto E; Rappuoli R
    Eur J Immunol; 2008 Aug; 38(8):2068-71. PubMed ID: 18651701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.
    Van Hoeven N; Joshi SW; Nana GI; Bosco-Lauth A; Fox C; Bowen RA; Clements DE; Martyak T; Parks DE; Baldwin S; Reed SG; Coler RN
    PLoS One; 2016; 11(2):e0149610. PubMed ID: 26901122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.